Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01462812 · ClinicalTrials.gov registry record · Phase 3
Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine
A Phase 3 study, sponsored by Optinose US.
- Completed
- Registry status
- Phase 3
- Development phase
- 223
- Enrollment target
NCT01462812 is a Phase 3 study that has completed, run by Optinose US. The registered enrollment target is 223 participants.
The verdict
NCT01462812, a Phase 3 study, has completed, sponsored by Optinose US.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 223 participants
- Enrollment target
Study Summary
The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.
Interventions
- DRUG Placebo
- DRUG Sumatriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01462812
The ClinicalTrials.gov registry entry for NCT01462812 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Optinose US, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01462812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01462812 about?
NCT01462812 is a clinical study titled "Safety & Efficacy of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine". The study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN Device can reduce the pain and symptoms associated with migraine headaches.
What is the current status of trial NCT01462812?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 223 participants. The study started on 2011-01. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01462812?
The interventions under investigation include: Placebo (DRUG), Sumatriptan (DRUG).
Who is sponsoring clinical trial NCT01462812?
This trial is sponsored by Optinose US, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.